1. SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity

   • L. C. Panasci
   • Daniela Marcantonio
   • Adrian J. Noë

   REVIEW Pages: 505 - 508

2. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies

   • S. Webber
   • Charlotte A. Bartlett
   • Bhasker V. Shetty

   ORIGINAL ARTICLE Pages: 509 - 517

3. The integrity of cisplatin in aqueous and plasma ultrafiltrate media studied by 195Pt and 15N nuclear magnetic resonance

   • K. M. Brière
   • Rakesh Goel
   • Ian C. P. Smith

   ORIGINAL ARTICLE Pages: 518 - 524

4. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines

   • Y. Kano
   • Miyuki Akutsu
   • Yasuo Yazawa

   ORIGINAL ARTICLE Pages: 525 - 530

5. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies

   • S. M. Sugarman
   • Y. Y. Zou
   • Roman Perez-Soler

   ORIGINAL ARTICLE Pages: 531 - 538

6. Penetration of intravesical doxorubicin in human bladders

   • M. G. Wientjes
   • Robert A. Badalament
   • Jessie L.-S. Au

   ORIGINAL ARTICLE Pages: 539 - 546

7. Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase

   • M. Belanich
   • Terri Randall
   • Daniel B. Yarosh

   ORIGINAL ARTICLE Pages: 547 - 555

8. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance

   • Yan-Ping Hu
   • Sophie Jarillon
   • J. Robert

   ORIGINAL ARTICLE Pages: 556 - 560

9. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

   • A. M. Hussein
   • William P. Petros
   • William P. Peters

   ORIGINAL ARTICLE Pages: 561 - 568

10. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus

    • G. F. Fleming
    • Everett E Vokes
    • M Eileen Dolan

    ORIGINAL ARTICLE Pages: 569 - 573

11. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistant to cisplatin treatment

    • G. P. Raaphorst
    • S. Doja
    • C. E. Ng

    ORIGINAL ARTICLE Pages: 574 - 580

12. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

    • N. J. Meropol
    • Yousef M. Rustum
    • Patrick J. Creaven

    ORIGINAL ARTICLE Pages: 581 - 586

13. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer

    • K. Sakai
    • Goro Kosaki
    • Akira Oshima

    ORIGINAL ARTICLE Pages: 587 - 592

14. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine

    • Michael P. Gosland
    • Mark N. Gillespie
    • S. M. Aziz

    ORIGINAL ARTICLE Pages: 593 - 600

15. Transforming growth factor-β in in vivo resistance

    • B. A. Teicher
    • Sylvia A. Holden
    • Guan Chen

    ORIGINAL ARTICLE Pages: 601 - 609

16. Carboplatin and vinorelbine in advanced non-small-cell lung cancer

    • P. Pronzato
    • Ermanno Ghio
    • Antonella Vigani

    CLINICAL TRIAL REPORT Pages: 610 - 612

17. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer

    • C. Gridelli
    • Antonio Rossi
    • Angelo Raffaele Bianco

    CLINICAL TRIAL REPORT Pages: 613 - 615

18. Is there a circadian variation in plasma concentrations of etoposide given by prolonged continuous infusion?

    • Yuichi Ando
    • Hironobu Minami
    • K. Shimokata

    SHORT COMMUNICATION Pages: 616 - 618